Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NURSERY: Suptavumab for RSV Prevention in Preterm Infants
NCT02325791Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of suptavumab in respiratory syncytial virus infection (RSV), sponsored by Regeneron Pharmaceuticals. Started Jul 2015; status: completed.
02
Drugs
suptavumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02325791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325791.